Vimarsana
Biggest News Aggregation in the World

Page 14 - Michael Kaiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Michael Kaiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Michael Kaiser Today - Breaking & Trending Today

Hockert hired as Wahpeton High School's next principal | Local News Stories - Vimarsana News

Hockert hired as Wahpeton High School's next principal | Local News Stories

With an 8-0 vote Wednesday, Jan. 10, the Wahpeton School Board approved hiring Steve Hockert as principal of Wahpeton High School beginning in the 2024-2025 education year. The vote also

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences - Vimarsana News

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s...

Wahpeton fifth graders graduate from D.A.R.E - Vimarsana News

Wahpeton fifth graders graduate from D.A.R.E

Officer Lisa Page, Wahpeton Police Department, serves as Wahpeton Public School District’s Resource Officer (RO). Resource officers are the individuals inside schools to ensure everyone's safety. Resource officers are not

'Truth About Reading' documentary shown in Wahpeton | Local News Stories - Vimarsana News

'Truth About Reading' documentary shown in Wahpeton | Local News Stories

More than half of Americans between the ages of 16-74 read below a sixth grade level. Out of nearly 200 countries in terms of literacy rate, measured by the age

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights - Vimarsana News

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials

Source: yahoo.com